Display options
Share it on

J Neurol. 2004 Nov;251(11):1297-303. doi: 10.1007/s00415-004-0619-5.

Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis.

Journal of neurology

Helen Tremlett, Joel Oger

Affiliations

  1. Department of Medicine (Neurology) rm S159, Vancouver Hospital and Health Sciences Centre, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada. [email protected]

PMID: 15592724 DOI: 10.1007/s00415-004-0619-5

Abstract

This review explores the salient issues surrounding liver injury and liver monitoring associated with beta-interferon (IFNB) treatment for multiple sclerosis (MS). Post-marketing studies have found a higher proportion of IFNB-treated MS patients with elevated aminotransferases than reported in the pivotal clinical trials. Although the risk of severe liver injury appears small, the true incidence is unknown. Post-marketing studies have shown that the greatest period of risk for the development of liver test abnormalities appears to be in the first year of IFNB treatment. The risk also increases with the more frequently administered, higher-dosage IFNBs. Males are more likely than females to develop elevated aminotransferases (> upper normal limit), although females appear at a greater risk of severe liver injury. Of the commonly used biochemical liver tests, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP) and bilirubin appear the most useful for routine monitoring of IFNB treatment. Whilst many other factors can affect liver test results, including obesity, alcohol, concomitant medications, co-morbidities and theoretically even MS itself, regular liver testing both prior and during IFNB therapy might help minimise Type A or dose/frequency dependent aminotransferase elevations. However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly.

References

  1. J Gastroenterol. 2002;37(8):617-25 - PubMed
  2. Am J Gastroenterol. 1996 Oct;91(10 ):2233-4 - PubMed
  3. Ann Neurol. 1996 Mar;39(3):285-94 - PubMed
  4. Semin Oncol. 1992 Oct;19(5):551-65 - PubMed
  5. J Clin Pharm Ther. 2001 Dec;26(6):437-44 - PubMed
  6. Arterioscler Thromb. 1992 Sep;12(9):1053-62 - PubMed
  7. Lancet. 1998 Nov 7;352(9139):1498-504 - PubMed
  8. Can J Gastroenterol. 1998 Sep;12(6):417-21 - PubMed
  9. Ann Intern Med. 2002 Jul 2;137(1):49-51 - PubMed
  10. Neurology. 2001 May 22;56(10):1416 - PubMed
  11. Ann Intern Med. 2001 Feb 20;134(4):345 - PubMed
  12. Mil Med. 1978 Aug;143(8):548-51 - PubMed
  13. J Neurol. 2002 Jan;249(1):50-6 - PubMed
  14. Atherosclerosis. 1987 Oct;67(2-3):261-7 - PubMed
  15. Arthritis Rheum. 2002 Jul;46(7):1851-6 - PubMed
  16. Am J Med. 1992 Apr;92(4):433-6 - PubMed
  17. Neurology. 1993 Apr;43(4):655-61 - PubMed
  18. N Engl J Med. 1989 Sep 14;321(11):762-3 - PubMed
  19. Brain. 2002 May;125(Pt 5):952-60 - PubMed
  20. Ann Ital Med Int. 2000 Jul-Sep;15(3):214-7 - PubMed
  21. Pharmacol Ther. 2001 Nov-Dec;92(2-3):147-63 - PubMed
  22. Am J Clin Oncol. 1993 Apr;16(2):159-63 - PubMed
  23. Can J Neurol Sci. 1987 Aug;14(3 Suppl):513-7 - PubMed
  24. J Hepatol. 2000;32(1 Suppl):77-88 - PubMed
  25. Drug Saf. 2003;26(11):815-27 - PubMed
  26. Acta Physiol Scand. 1999 Nov;167(3):259-65 - PubMed
  27. Regul Toxicol Pharmacol. 1998 Apr;27(2):119-30 - PubMed
  28. N Engl J Med. 2000 Apr 27;342(17):1266-71 - PubMed
  29. AMA Arch Neurol Psychiatry. 1954 Apr;71(4):405-24 - PubMed
  30. Br J Clin Pharmacol. 1988 Jul;26(1):1-5 - PubMed
  31. J Gastroenterol. 2002 Jan;37(1):40-6 - PubMed
  32. Neurology. 1990 Sep;40(9):1427-32 - PubMed
  33. Am J Med. 1999 Feb;106(2):267-8 - PubMed
  34. Lancet. 1989 May 20;1(8647):1143 - PubMed
  35. Neurology. 2001 Oct 23;57(8):1363-70 - PubMed
  36. Neurology. 1998 Feb;50(2):570-1 - PubMed
  37. Am J Med Sci. 1999 May;317(5):336-40 - PubMed
  38. Lancet. 1967 Apr 22;1(7495):896 - PubMed
  39. Autoimmunity. 2003 May;36(3):133-41 - PubMed
  40. J Hepatol. 1990 Sep;11(2):272-6 - PubMed
  41. N Engl J Med. 2003 Jul 31;349(5):474-85 - PubMed
  42. Gut. 1991 Jun;32(6):715-7 - PubMed
  43. Clin Chem Lab Med. 2000 Mar;38(3):209-13 - PubMed
  44. Am J Gastroenterol. 2002 Mar;97(3):767-8 - PubMed
  45. Lancet. 2000 Feb 19;355(9204):591-2 - PubMed
  46. Arch Intern Med. 2002 Apr 8;162(7):811-5 - PubMed
  47. Neurology. 2002 Jan 22;58(2):169-78 - PubMed
  48. Neurology. 2004 Feb 24;62(4):628-31 - PubMed

Substances

MeSH terms

Publication Types